UniQure (QURE) said Thursday the Independent Data Monitoring Committee for a phase 1/2 trial of AMT-162 to treat amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 gene recommended going ahead with enrollment in the second group after reviewing safety data from the first group in the study.
The committee's review didn't identify any "significant safety concerns," the company said, adding it plans to start enrollment of the second dose group in Q1 2025.
The trial is being conducted in the US and has three dose-escalating groups with up to four patients each getting a short course of immunosuppression before and after an intrathecal infusion of AMT-162, the company said.
Price: 15.27, Change: +0.03, Percent Change: +0.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.